Johnson & Johnson reports TREMFYA benefits in axial psoriatic arthritis

Key highlights
  • At Week 24, BASDAI scores improved by 3.3 points with TREMFYA Q4W and 2.9 points with Q8W, versus 2.1 points with placebo.
  • MRI-assessed sacroiliac inflammation scores fell by 7.1 points with Q4W and 5.2 points with Q8W, compared with 2.4 points with placebo.
  • The STAR study enrolled 411 biologic-naïve adults and included a 24-week placebo-controlled period followed by 24 weeks of active treatment.
  • No new safety signals were identified; the study safety profile was consistent with TREMFYA’s established profile in psoriatic disease.

Phase 4 study results

Johnson & Johnson reported results from the Phase 4 STAR study of TREMFYA (guselkumab) in biologic-naïve adults with active psoriatic arthritis and MRI-confirmed axial inflammation. The trial met its primary and major secondary endpoints, showing improvements in axial symptoms and MRI-assessed sacroiliac joint inflammation versus placebo at Week 24.

Mean BASDAI scores improved by 3.3 points with TREMFYA 100 mg every four weeks (Q4W) and 2.9 points every eight weeks (Q8W), compared with 2.1 points with placebo. ASDAS-CRP scores improved by 1.5 and 1.3 points, respectively, versus 0.8 points with placebo. The company noted that Q4W dosing is not approved in the U.S.

MRI and safety findings

Sacroiliac joint inflammation, measured by MRI using the SPARCC score, decreased by 7.1 points with Q4W and 5.2 points with Q8W, compared with 2.4 points with placebo. Improvements in reported symptoms included spinal pain, stiffness, fatigue, joint symptoms and tenderness. The study also reported skin clearance with both dosing schedules. No new safety signals were identified.

Study design

STAR enrolled 411 participants. It was a randomized, double-blind, placebo-controlled study with a 24-week placebo-controlled treatment period followed by 24 weeks of active treatment. Participants had active psoriatic arthritis, MRI evidence of axial inflammation and elevated C-reactive protein despite previous treatment with non-biologic DMARDs, apremilast and/or NSAIDs.

Source: J&J

chemXplore Weekly

The week’s project milestones and project news from the chemical industry, free every Wednesday.

Free. One email a week. Unsubscribe any time. See our Privacy Policy.

Related articles

25 September 2026
Johnson & Johnson: TREMFYA first IL‑23 inhibitor to show spinal pain and stiffness benefit in axial PsA STAR study

Phase 4 STAR trial: guselkumab improved BASDAI at Week 24, reduced ASDAS‑CRP and MRI sacroiliac inflammation in biologic‑naïve axial PsA; safety profile consistent.

19 October 2026
Johnson & Johnson: TREMFYA sustains perianal fistula remission through 48 weeks in Phase 3 FUZION

In FUZION, TREMFYA 100 mg q8w combined remission rose from 28% at Week 24 to 35% at Week 48; 200 mg q4w rates remained stable and safety was consistent through one year.

13 October 2026
Johnson & Johnson TREMFYA shows sustained remission through three years in Crohn’s disease

Phase 3 GALAXI 2 and 3 Week 144 LTE data report high rates of clinical, corticosteroid‑free and endoscopic remission with two maintenance regimens; 74% remained on treatment at three years.

15 July 2026
Johnson & Johnson Q2 2026 results and raises 2026 outlook

Quarterly sales topped $25.3B; adjusted net earnings and EPS rose, free cash flow improved, and full-year revenue guidance was raised above $100B for the first time.

28 May 2026
Johnson & Johnson: FDA approves TREMFYA label update for PsA joint‑damage inhibition

APEX Phase‑3b: in biologic‑naïve PsA patients, 24‑week results met ACR20 and significantly inhibited structural joint damage vs placebo; placebo switchers had 57% less radiographic progression to Week 48; safety unchanged.